Pharmaceutical Executive
PricewaterhouseCooper's "Global Construction 2020" report predictions
The "Global Construction 2020" report, sponsored by PwC, predicts that, between 2010 and 2020, nearly $100 trillion will be spent on construction globally. India would overtake Japan and become the third-largest construction market by 2018, after China and the US. But while many of India's high-growth sectors, including pharma, are set to nurture such local construction projects, safety standards are still less respected than in many Western countries. Many of the MNCs therefore approach international players, renowned for their construction management skills.
"Roughly 50% of our clients, including non-pharma, have an interest in the fact that Australia-headquarterd Cockram Construction has established itself in India," explains Robert Sirgiovanni, the company's director of Asia and International operations. Having successfully completed his first project with Pfizer in India, Sirgiovanni still needs to use local contractors to do the physical work on the site. "To do so, we go through a very rigorous qualification process. We rely on ourselves to educate and train the people, and have a very comprehensive induction process at the start of the project. Apart from initiatives such as videos in local languages and dialects, we have our people on the ground, who make sure that these workers follow the safety practices," he says. "There are a lot of traps in India, which makes it key to be there early and find people that have experience on the ground. There are a lot of success stories, showing how the day-to-day challenges are outweighed by the many benefits."
With two million man hours and no loss through injury, Cockram's efforts to raise safety standards in India have indeed prevailed. "We are looking at the long term, and see no reason why India cannot become the next China for Cockram Construction", Sirgiovanni says. For now, he hopes to turn India into his third-largest market, after Australia and China.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.